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Summary 
While studying the T cell receptor (TCR) repertoire of normal individuals, we found that more 
than  20%  of adults  have low levels  of circulating  VB3.1 +  T  cells  in  both  CD4  and  CD8 
populations. A similar frequency was found in fetal cord blood samples,  suggesting that in most 
cases,  the Vfl3.1 l~  phenotype is inherited.  In support of this conclusion, children  expressing 
low levels were only found in families where one of the parents expressed this phenotype.  In 
two large families,  genetic studies showed that low expression was a recessive trait and dependent 
on inheritance of particular TCR VB gene complexes. Family members with the low phenotype, 
however, expressed VB3.1 genes with normal sequences and expressed normal levels of receptor 
per cell.  Results from these families suggest that up to 50% of normal individuals may carry 
a VB3.1 allele that is defective in its ability to rearrange effectively. In another large family, low 
expression in one individual  was shown not to be determined by genes within the TCR VB 
gene or major histocompatibility complexes, suggesting a different mechanism for low VB3.1 + 
T  cells.  Overall,  our results describe novel mechanisms  that result in low levels of Vfl3.1 + T 
cells  in  a relatively large  subset of the normal  human  population. 
S 
tudies in mice have shown that different mechanisms may 
lead to low levels of expression of particular  TCR V3 
genes (now referred to  as TCRBV or VB genes).  For ex- 
ample,  a deletion within  the VB complex of some strains 
leads to the complete absence of T cells bearing certain VBs 
(1-3). Missing V3 subsets in mice can also be the result of 
polymorphism in specific VB structural genes (3-5). In ad- 
dition to these mechanisms, expression of endogenous mouse 
mammary tumor virus (MMTV) superantigens or exposure 
to bacterial superantigens can lead to dramatic reductions in 
the percentage of T  cells bearing target V/3s (for a review 
see reference 6). Although usually present in both the CD4 + 
and CD8 + populations, T cell subset deletions mediated by 
superantigens are not complete. Thus, unlike mice carrying 
VB gene deletions or structural  gene mutants,  there is ex- 
pression of residual cells bearing the specific V3s involved 
in recognition. 
Thus far, studies in humans have only convincingly shown 
low V3 expression related to alterations in the corresponding 
structural VB gene. For example, coding region changes ac- 
count for low levels  of V36.7a + T  cells because of a lack 
of mAb binding to the V36.7b product (7). Relatively fre- 
quent nonfunctional alleles of the VB6.1 (TCRBV6S1) and 
VB18 loci have also been described (8-10). There are no descrip- 
tions in humans of TCK repertoire deletions related to en- 
dogenous superantigen  expression.  In this report,  we ana- 
lyze the  genetic  mechanisms  responsible for low levels  of 
V~3.1 + T  cells in a relatively large subset of normal indi- 
viduals. 
Materials and Methods 
Sample Preparation.  Mononuclear cells were isolated from pe- 
ripheral blood or cord blood samples by FicoU-Hypaque density 
gradient separation, and used for analysis of TCK VB expression 
and preparation of RNA (11). For genetic studies in families, neu- 
trophils were also isolated from the pellet during gradient  separa- 
tion of mononuclear cells and used for preparation of genomic DNA. 
Immunofluorescence Analysis.  Mononuclear  cells were stained 
using biotinyhted mAb directed to V/32, V/33.1, VB5.1, Vfl5.2/5.3, 
VB6.Ta, Vfl8.1/8.2,  V/312, V/313.1, Vfl13.2, and VB17 (12-15). 
Streptavidin-PE (Fisher Biotech,  Pittsburgh,  PA) was used as a 
second-step  reagent.  Samples were  also  stained  with  FITC- 
conjugated mAbs directed to CD4 and CD8 (both from Becton 
Dickinson  & Co.,  Mountain  View, CA). Fluorescence intensity 
was analyzed with a cytofluorograph (Epics Profile; Coulter Corp., 
Hialeah, FL), and at least 104 cells were analyzed for each anti- 
body combination. 
The specificity  of the 8F10 mAb was assigned based on its ability 
to stain T cell hybridomas transfected with a DNA construct con- 
taining VB3.1 as described (15), but not their untransfected parents 
or hybridoma cells expressing other human V/3 elements (data not 
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T cell clones was typed for surface  expression with the 8F10 mAb 
and for VB3.1 mRNA expression by PCR (11). Additionally,  stim- 
ulation of peripheral blood cells with the 8F10 mAb resulted in 
a selective  increase of VB3.1 mRNA expression (13, and Donahue, 
J. P., P. Marrack, J. Kappler, and B. L. Kotzin, unpublished obser- 
vations). 
Sequencing of TCRBV3S1 Genes.  TCRBV3S1 (hereafter called 
VB3.1) sequences were obtained by amplifying  cDNA derived  from 
unstimulated cells using PCR with oligonucleotides specific for 
the VB3.1 leader (GTCAGAATTCCACCATGGGAATCAGGC- 
TCCTCTGTC) and TCRBC (CGGGTGGGAACACCTTGTTC- 
GGATCCTC). Amplified  DNA was cloned  into pTZ18R (Pharmacia 
Fine Chemicals, Piscataway, NJ) using EcoRI and BamHI sites, 
or into the pCR  TM cloning vector as specified  by the manufacturer 
(Invitrogen, San Diego, CA). The ligation product was transformed 
into competent Escherichia coli cells (Invitrogen), and colonies con- 
taining appropriate inserts were chosen randomly for sequencing. 
DNA sequencing was performed by the dideoxy method using Se- 
quenase (United States Biochemical Corp.,  Cleveland, OH). At 
least five cDNA clones derived from each sample were sequenced. 
Identification of Polymorphisms within the  TCRB  Gene Com- 
plex.  Previously  described  VB gene polymorphisms  were used pri- 
marily to genetically type family members and to determine the 
inheritance pattern in families. For example, in Families A and B, 
we utilized polymorphisms in simple sequence repeats (simple se- 
quence length polymorphisms [SSLPs]) contained within the VB6 
subfamily ofgene segments as described (16). Sequences  of the oli- 
gonucleotides used for PCR amplification were as described (16). 
PCR employed a thermal cycler (Cetus/Perkin Elmer; Emeryville, 
CA). In each reaction, 100 ng of genomic DNA was mixed with 
primers (0.3 #M final concentration),  1.0 U of Taq polymerase 
(Perkin Elmer), and 20/~M each of dNTPs in a total volume of 
50/~1. Amplification was performed for 35-40 cycles, with 1 rain 
of denaturation at 95~  1 rain of annealing at 55 ~  and 2 rain 
of extension at 72  ~ PCR products were separated on a 15% poly- 
acrylamide gel, and visualized with ethidium bromide and UV ir- 
radiation. 
In Family A, we also utilized PCR and polymorphisms within 
the TCRBC loci as described (17). Polymorphisms in two regions 
identified as Cfl21 and Cfl25 (17) could be identified by changes 
in BgllI and KpnI restriction sites, respectively.  Primers utilized 
for PCR were as described (17) and PCR conditions were identical 
to those described above. After precipitation of 20 #1 of the PCR 
product, digestion was carried out with 2 U//xg DNA of enzyme 
at 37 ~ overnight. Undigested and digested aliquots were separated 
on a 2% agarose gel and visualized with ethidium bromide and 
UV irradiation. 
In Family B, previously reported polymorphisms in the VB6.1 
structural genes were also utilized (8). One of the mutations at 
amino acid position 62, eliminates a BsiE1 restriction enzyme site. 
Primers  utilized  were 5'-GTTCTCAACTTGTGTCTCCG  (+ 
strand) and 5'-GAGATACACGGCTGAGTC  (-  strand). 25 #1 of 
amplified  product was digested with 2 U//zg DNA of BsiE1 (New 
England Biolabs Inc., Beverly,  MA) overnight at 55~  Undigested 
and digested products were separated on a 15% polyacrylamide  gel 
and visualized by ethidium bromide staining. 
In Family C, typing of maternal TCRB haplotypes utilized 
Southern analysis and a previously described RFLP defined by a 
BgllI restriction site in the TCRBC2 gene segment (18). In addi- 
tion, a VB3.1 polymorphism was utilized to determine inheritance 
of paternal VB gene complexes. To determine the presence of the 
paternal allele, cDNA from unstimulated  PBMC was amplified  using 
VB3.1 and TCRBC specific  primers utilized above for sequencing. 
This fragment was then reamplified  using internal oligonucleotides 
specific for  VB3.1 (GTGAGAATTCCACCTGAAAGTAACC- 
CAGAGCTCG) and  TCRBC  (TTCTGATGGCTCAAACAC). 
Fragments were digested with AatlI overnight before analysis on 
a gel. 
Results 
Variable Percentages of Vl~3 +  T Cells in Adult and Fetal Cord 
Blood.  We examined the peripheral blood TCK repertoire 
in a group of unrelated normal adults to look for possible 
deletions of specific Vfl subsets.  These studies were accom- 
plished first using a quantitative PCR technique (11) and sub- 
sequently using flow cytometry  with mAb directed to T cells 
bearing  Vfl2,  Vfl3.1,  V35.1,  VflS.2,  Vf16.7,  Vfl8.1/8.2, 
Vf112, Vfl13.1, Vfl13.2, and Vf117. By PCK analysis and with 
a mAb directed to Vfl3.1  (clone 8F10),  we noted a broad 
range in the percentage of Vfl3.1 + T  cells in the normal 
population, and discovered several individuals with distinctly 
low levels (staining data are shown in Fig. 1 a). Unlike results 
with some of the other anti-Vfl antibodies, low levels of 
Vfl3.1 + cells, whe  n  present,  occurred in both the CD4 + 
and CD8 + populations. 7 of 31 unrelated adults studied (or 
23%) had low percentages of Vfl3.1-bearing T cells, defined 
as x<2.0% ofCD4 + and CD8 + T cells. Most of these indi- 
viduals were studied multiple times over several months and 
the percentage of Vfl3.1 + T cells remained remarkably stable 
in all cases (data not shown). 
We also examined the TCR repertoire of fetal cord blood 
samples (Fig.  1 b).  5 of 25 samples contained low percent- 
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Figure  1.  Percentages  of T cells expressing  VB3.1 in adult peripheral 
blood (a) or fetal  cord  blood (b). Cells from each sample  were stained  for 
both Vfl3.1 (clone 8F10) and either CD4 or CDS, and the percentages 
of each population staining positive are shown. 
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The frequency of low values ('~20%) was similar to that ob- 
served for adults (Fig. 1 a),  suggesting  that infection after 
birth  does  not  account  for  most  of the  cases with  the 
V33.1 l~  phenotype. 
We carefully examined the density of V33.1 expression per 
cell, as determined by mean channel of fluorescence inten- 
sity, in a large number of different individuals with both low 
and high percentages of V33.1 + cells in blood. The density 
was identical regardless of the percentage of  positive cells (data 
not shown). 
Inheritance Pattern  for the Vfl3.1 u~ Phenotype and Contribu- 
tion of TCR and MHC genes.  We searched for families in 
which the mother and father expressed divergent levels of 
V33.1 + T cells. Of the first 13 sets of parents studied, 7 had 
one spouse with a low level of V33.1-expressing  T cells. In 
these seven families, the frequency of children with low V33.1 
levels (<2% in both CD4 + and CD8 + subsets) was 12 of 
30 compared with 0 of 23 in the other six families (p <0.001 
by Fisher's exact test).  These results strongly suggest that 
low levels of V33.1 + T  cells are determined genetically. 
We analyzed three of the above families with the largest 
number of individuals for the contribution of VB or MHC 
genes to the V33.1  phenotype. The analysis of Family A is 
shown in  Fig.  2 a.  The mother expressed low levels of 
V33.1 + T cells in both CD4 + and CD8 + subsets, whereas 
the father did not express this phenotype. Six children were 
analyzed, of which three expressed the V33.1 l~  phenotype. 
Other T cell subsets quantitated by monoclonal anti-V3 an- 
tibodies were not strikingly different among family members 
(only data for V38.1/8.2  are shown). As shown in Fig. 2 
a, the inheritance of MHC haplotypes in this family was in- 
dependent of V33.1 § T cell levels. It is interesting to note 
that expression of the low phenotype correlated with in- 
heritance of one of the TCRB complexes from the father, 
who did not express the low phenotype (Fig.  2 a).  The 
statistical likelihood of this happening by chance is p  =  0.05 
(by Fisher's exact test). Either of the mother's TCRB com- 
plexes appeared to allow for the low phenotype in the children. 
This analysis of Family B is shown in Fig.  2 b.  Again, 
the mother expressed the low phenotype that was expressed 
by four of the seven children. V33.1 levels in the other three 
children were actually higher than those expressed by the fa- 
ther. 5 wk later, repeat studies of three children, including 
two with the low phenotype, showed identical V33.1 per- 
centages. As shown in Fig. 2 b, MHC haplotypes inherited 
from the mother or father did not correlate with V33.1 + 
T cell levels. However, similar to Family A, this family also 
showed a concordance of the V33.1 l~  phenotype with one 
of the paternal TCRB gene complexes (p =  0.03 by Fisher's 
exact test). Again, either TCRB complex from the mother, 
who expressed the low phenotype, allowed for low levels in 
her offspring. 
One additional family (Family C) with the largest number 
of available individuals was studied  to determined the im- 
portance of TCRB or MHC genes (Fig. 2 c). The mother 
(II-2) exhibited a V33.1 l~  phenotype as did one sister (II- 
3).  Of the eight children examined, only one child (III-4) 
was V33.1 l~  These phenotypes remained stable during the 
12-mo period in which the family was studied. For example, 
percentages  of peripheral  blood CD4 + T  cells expressing 
V33.1 in samples taken several months apart from the father 
(II-1) were 4.9,  5.7, and 5.0%.  In contrast, values for the 
mother (II-2) were 1.5, 1.7, and 1.3%, and values for child 
III-4 were 2.0 and 1.9%. 
Inheritance of MHC haplotypes in Family C is shown in 
Fig. 2 c. In several individuals, the same MHC type was as- 
sociated with disparate V33.1  expression, indicating that a 
particular  MHC  type  was  not  sufficient  to  explain  the 
V33.1 l~  phenotype. 
During the sequencing of VB3.1 genes expressed in Family 
C, a new VB3.1 allele (designated TCRBV3SI*2[N]) was 
identified in the father, which differs from previously pub- 
lished sequences  (designated  TCRBV3SI*I [19, 20]) by a single 
nonproductive change (A ~  G) in the third position of the 
threonine codon at position 84. Although it does not alter 
the amino acid sequence, this change does generate a unique 
AatlI restriction site, which was useful for identifying the 
paternal VB complex inherited among family members. Using 
this  AatlI  polymorphism and  a  previously  characterized 
genomic TCRBC2 BgllI polymorphism (18), we identified 
two individuals who inherited the same VB complexes but 
who had different V33.1 phenotypes (III-4 and III-8). 
VB3.1 Gene Sequences Expressed by Individuals with the Low 
Phenotype.  Expressed VB3.1 gene sequences were analyzed 
in a number of different individuals to determine if coding 
region polymorphisms contributed to low levels of V33.1 § 
T cells. Table 1 shows that structural VB3.1 gene alterations 
do not account for differences in V33.1  expression. Table 1 
also shows that a relatively large ,traction of the cDNA clones 
from V33.1 l~  individuals represent nonfunctional rearrange- 
ments ~  <0.005, compared with sequences from individ- 
uals not expressing the low phenotype). It is important to 
note that the coding region of the nonfunctional clones also 
matched the TCRBV3SI*I  sequence. 
Discussion 
We initiated these studies of human TCR repertoire for- 
mation by analyzing lymphocytes from normal individuals 
for V3 expression using both quantitative PCR and different 
anti-VB mAb.  Although considerable variation was found 
for many V3s, only a few, such as V/~3, were found to be 
expressed at distinctly low levels in both CD4 + and CD8 + 
subsets in some individuals.  Our results show that >20% 
of normal adults express the V33.1  l~  phenotype. A similar 
frequency in fetal cord blood samples and a strong inheritance 
pattern in family studies strongly support the hypothesis that 
the V33.1 l~  phenotype is genetically determined in most 
cases. 
In  two  families studied,  the V33.1 l~  phenotype cor- 
related perfectly with inheritance of one TCRB complex from 
the parent who was not low. Either allele from the V33.1 l~ 
parent was sufficient for expression of the low phenotype. 
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heritance of MHC haplotypes,  and inheritance  of 
TCRB complexes in Family A. Family members 
studied,  including  siblings III-1  to  1II-6  (ages 
24-11),  are shown, and individuals with <2.0% 
V/$3.1*  T  cells in both  the CD4 §  and  CD8 + 
subsets  are  indicated by shading.  The  paternal 
grandmother,  indicated by hatching, could not 
be located for the study.  MHC  haplotypes are: 
A - A2, B35, Cw4, DR4, DR53, DQw3; B - A3, 
B62, Cw3, DR11,  DR52,  DQw3;  C  - A3, B7, 
Cw7,  DR1,  DQwl;  and D  -  A24,  B7,  Cw7, 
DR11, DK52, DQw3. TCRB haplotypes were re- 
vealed by polymorphisms in a VB6.7 SSLP (16). 
In  addition, inheritance of the paternal TCRB 
haplotypes was confirmed using a BgllI polymor- 
phism in TCRBC2 (17). Thus, one of the paternal 
alleles carries a Bglll restriction site that cuts the 
595-bp PCR fragment into fragments of 465 and 
130 bp (designated as allele  F). (b) Analysis  of V33.1 
expression,  inheritance of MHC haplotypes,  and 
inheritance  of TCRB gene haplotypes in Family 
B. Family  members studied, including siblings II1-1 
to Ili-7 (ages 17-3),  are shown,  and individuals 
with <2.0% V/~3.1 + T  cells in both the CD4 § 
and CD8 + subsets are indicated by shading.  The 
maternal grandfather,  indicated by hatching,  was 
not studied. MHC haplotypes are: A - A2, B57, 
Cw6, DR15, DQwl; B - A24, B51, Cwl, DR7, 
DR53, DQw2; C - A1, B27, Cwl, DKS, DQw4; 
D  - A24, B44, Cw3, DR4, DR53, DQw3;  and 
E  -  A2,  B51, Cwl,  DK7,  DK53,  DQw2.  In- 
heritance of maternal TCRB haplotypes (G and 
/4) was determined by an SSLP in the VB6.7 gene 
(16). Inheritance of paternal TCRB haplotypes was 
determined by a BsiE1 polymorphism in the VB6.1 
gene (8). One paternal allele (F) and maternal al- 
lele (/4) carries a BsiE1 restriction site that cuts 
the 300-bp product into two bands of ,'0220 and 
,o80 bp. Assignment of genotypes in the children 
was  possible  by  knowing  inheritance  of  the 
maternal alleles. (c) Analysis of V/~3.1 expression, 
inheritance  of MHC haplotypes, and inheritance 
of TCRB haplotypes in Family C. Family members 
studied, including siblings III-1 to III-8 (ages 19-3), 
are shown, and individuals with ~<2.0% V/~3.1  * 
T cells in both the CD4 + and CD8 + populations 
are indicated by shading. The maternal grandfather, 
who could not be located for study, is indicated 
by hatching.  MHC haplotypes are: A - A2, B8, 
Cw7, DR15, DQwl; B - A31, B18, DR7, DR53, 
DQw2;  C  - A2, B27,  Cwl, DK11, DR52,  DQw3;  and D  - A30, B18, CwS, DK2, DQwl.  TCRB inheritance was determined by polymorphism 
in the VB3.1 gene and a BgllI RFLP in the TCRBC2 region. In addition, inheritance of alleles in II-2, II-3, and 11-4 was determined with a VB6.7 
SSLP as described for Families A  and B. Maternal (II-2) alleles are designated G  and H, and are inherited from the maternal grandfather (G1, G~) 
or grandmother (H1,  H2).  A  single nucleotide change from the previously published TCRBV3SI*I  sequence was found in the father but not the 
mother. The change (A --- G in the third position of the threonine codon at amino acid number 84) results in a unique AatlI restriction site in this 
allele (F), which digests the 405-bp PCR product into bands of 266 and 139 bp. A Bglll polymorphism in one maternal TCRBC2 allele was identified 
by the presence  of a ,'o10 kb band (18) and allowed the analysis of inheritance of maternal alleles in the children. 
The  most  straightforward  explanation  for  these findings is 
that the low phenotype  is determined in a recessive fashion 
in these families. If this is the major mechanism  for the low 
phenotype in the human population, then nearly 20%  of in- 
dividuals must be homozygous  for the V~3.1 l~  allele, and 
as  predicted  by the  Hardy-Weinberg  equilibrium  for  allele 
frequency, nearly 50%  of individuals would then be expected 
to  carry  such  an  allele in  a  heterozygous  fashion. 
The  distribution  of V/~3.1  expression  in the  population 
overall suggested that there may be three phenotypes corre- 
sponding  to  the  three  possible  genotypes:  VB3.1 l~176 
VB3.11~  and  VB3.1 hish/hish.  However,  although  being 
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No. cDNA clones 
Study group  sequenced  No. wild type  No. in-flame 
General population 
V/~/3.1  n~176  (n  =  3)*  16  16~  15 
VB3.1  ~~  (n  =  4)*  22  22  13 
Family A 
II-2 (V/~3.1  l~  5  5  4 
111-6 (V~3.1  low)  5  5  3 
Family B 
II-1 (V~3.1  ~~176  5  5  5 
11-2 (V/~3.1  ~~  10  10  9 
II-7 (V/~3.1  l~  7  7s  4 
Family C 
II-1 (V/33.1  n~176  5  5If  5 
1I-2 (V~3.1  ~~  5  5  3 
* A minimum of five sequences were analyzed per individual. 
* Nucleotide sequences matched the published TCRBV3SI'1 allele sequence (19, 20). 
S  Two sequences carried different  single nucleotide  changes that were not present in the mother or father, and were felt to be errors introduced 
during PCR amplification. 
II These sequences contained a single nucleotide  difference  (see Fig. 2 c), which does not result in a change of the amino acid sequence. 
homozygous for the VB3.1 m~  allele appeared  to determine 
low expression in the families studied, heterozygous expres- 
sion did not necessarily determine a middle range of expres- 
sion. This is best illustrated in Family B, in which three het- 
erozygous children were identifed. Their levels of V/~3.1 § 
cells, however, were clearly at the high end of the total distri- 
bution. 
The polymorphism(s) in the VB3.1  allele that causes low 
expression  is currently unknown. However, it appears to be 
unique compared with other previously described VB gene 
polymorphisms (7-10).  Thus, the VB3.1 l~  allele is not ab- 
normal in its coding region. Functional VB3.1 mRNA and 
normal VB3.1 gene sequences were expressed in all individ- 
uals studied with the low phenotype. In addition, a relatively 
large number of nonfunctional VB3.1 rearrangements were 
found in individuals with the low phenotype, and in every 
case the VB3.1 coding sequence was normal. Finally, it should 
also  be  pointed out  that despite  the lower percentage of 
V~3.1 + cells in certain individuals,  the amount of TCR pro- 
tein expressed per cell is normal. We conclude that the VB3.1 
allele in these families is defective in its ability to rearrange 
normally. Although the increased frequency of nonfunctional 
rearrangements might be expected based on the low percentage 
of V/33.1 + T cells alone, this finding may also be secondary 
to the VB3.1  allele defect itself. 
Using techniques that quantitate V/3 mRNA, variability 
in VB3 expression has been observed by others (9, 21, 22). 
Vandekerckhove  et al. (22) reported that after implantation 
of fetal liver and thymus from V/~3-discordant  individuals 
into immunodeficient (SCID) mice, the V~3.1 l~  phenotype 
was determined before negative selection in the thymus and 
was dependent on the fetal liver rather than thymus donor. 
These  results  are  consistent  with  a  mechanism  whereby 
the V/33.1  l~  phenotype is determined by the TCRB gene 
complex. 
In one individual of a separate family, we found that the 
V/53.1 l~  phenotype was not determined solely by either VB 
or MHC genes. Although none of the children with disparate 
phenotypes was identical for both VB and MHC genotypes, 
it is unlikely that a combination of TCR and MHC genes 
is required for the low phenotype, since the amino acid coding 
region sequence of the VB3.1  genes in the family members 
did not differ. These results suggest a different mechanism 
for low Vfl3.1 + T cells in this individual, including the pos- 
sible existence of a V/$3.1-specific superantigen. However, it 
should be emphasized that the inheritance pattern in this family 
was unexpected in that only one of eight children expressed 
the low phenotype. Because our conclusions rest on this one 
individual, we cannot exclude an infectious exposure after 
birth that led to the low phenotype. Furthermore, since only 
one other sibling (III-8) was matched for inheritance of the 
paternal TCRB haplotype, we also cannot exclude a genetic 
recombination event that would explain higher levels in this 
child. 
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